Menopause Study

• Research type

  Research Study

• Full title

  Randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 on menopausal symptoms and quality of life in peri- and post-menopausal women

• IRAS ID

  344865

• Contact name

  Jordi Riera

• Contact email

  jordi.riera@kaneka.com

• Sponsor organisation

  Kaneka Americas Holding Inc

• Clinicaltrials.gov Identifier

  NCT06446869

• Duration of Study in the UK

  0 years, 6 months, 28 days

• Research summary

  This study has been designed to investigate the effect a probiotic supplement can have in mitigating the effects of menopause symptoms. As menopause symptoms are closely related oestrogen levels, it is hoped that the probiotic will be able to recirculate active oestrogen in the bloodstream to mitigate menopause symptoms.
  

• REC name

  London - Central Research Ethics Committee

• REC reference

  24/PR/0826

• Date of REC Opinion

  6 Aug 2024

• REC opinion

  Further Information Favourable Opinion